The biologics development and approval process for pharmaceutical companies around the world is typically long and complex, which increases the risk of inaccurately forecasting demand
By Steve Lam, Senior Vice President, Patheon’s Biologics Unit
Advertisement
Articles by By Steve Lam, Senior Vice President, Patheon’s Biologics Unit
Advertisement
Latest Updated Articles
- Dealing with biologics production uncertainty
Published: July 6th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Pharma Pulse: Long COVID Exercise Win, $150M Gene Editing Play, and Compounding Pharmacy Expansions
2
Strive Pharmacy Breaks Ground on Arizona HQ
3
Pharma Pulse: Pazdur Retires from FDA, While Public Trusts AMA Over CDC on Vaccines, and New Data Redefines Adherence as an Emotional Crisis
4
Cencora Accelerates Global 3PL Expansion With Major Investments in Cold Chain and Specialty Logistics
5
